Psoriasis

Monoclonal Antibody Attacks Condition On A Molecular Level

Published in Drug Week, April 6th, 2001

Psoriasis symptoms can be alleviated with Xanelim (efalizumab), one of a new class of targeted monoclonal antibody drugs, researchers said at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, March 18-23, 2001.

Additionally, Xanelim, also known as anti-CD11a, has demonstrated the potential for treating other inflammatory diseases.

In prior studies, Craig Leonardi, MD, Radiant Research, St. Louis, Missouri, and colleagues from throughout the United States, have found that Xanelim injected intravenously reduced lymphocyte infiltration, epidermal hyperplasia, and keratin 16 expression, which are associated with the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry